David Ilson, Florian Lordick. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Chemoradiotherapy/adverse effectsChemoradiotherapy/mortalityChemoradiotherapy, Adjuvant/adverse effectsChemoradiotherapy, Adjuvant/mortalityClinical Decision-MakingDisease ProgressionEsophageal Neoplasms/mortalityEsophageal Neoplasms/pathologyEsophageal Neoplasms/therapyEsophageal Squamous Cell Carcinoma/mortalityEsophageal Squamous Cell Carcinoma/pathologyEsophageal Squamous Cell Carcinoma/therapyEsophagectomyHumansNeoadjuvant Therapy/adverse effectsNeoadjuvant Therapy/methodsNeoadjuvant Therapy/mortalityNeoplasm Recurrence, LocalNeoplasm, ResidualRisk FactorsTime FactorsTreatment Outcome
Year: 2018 PMID: 30528077 DOI: 10.1016/S1470-2045(18)30662-4
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316